Metabolic dysfunction-associated steatotic liver disease and gallbladder polyp development: an observational study.
Fatty liver disease
Gallbladder diseases
Lifestyle
Metabolic syndrome
Obesity
Polyp
Risk factors
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
04
04
2024
accepted:
17
09
2024
medline:
29
9
2024
pubmed:
29
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
The influence of metabolic dysfunction-associated steatotic liver disease (MASLD) on gallbladder polyp development in both sexes remains elusive. Therefore, to clarify the role of MASLD in gallbladder polyp development, we investigated the longitudinal association between MASLD and gallbladder polyps. In this observational study, we included 5,527 gallbladder polyp-free patients who underwent > 2 health check-ups over > 2 years. Generalized estimation equations were used to analyze associations between MASLD and gallbladder polyp development according to repeated measures at baseline and the most recent stage. Gallbladder polyp development rates in men and women were 7.5% and 5.6% (p < 0.01), respectively. MASLD was not significantly correlated with gallbladder polyp development. Regarding the association between gallbladder polyp development (men: ≥6 mm and women: ≥5 mm) and the number of MASLD components following lifestyle habits, men and women with ≥ 4 MASLD components had odds ratios of 3.397 (95% confidence interval: 1.096-10.53) and 5.338 (1.054-27.04), respectively. Higher nonalcoholic fatty liver disease fibrosis scores were associated with significant risk of gallbladder polyp development in women (1.991, 1.047-3.785). Although MASLD influence on gallbladder polyp development differs by sex, close monitoring of patients with an increasing number of MASLD components is essential to prevent gallbladder polyp development. Specifically, men with ≥ 4 MASLD components should be monitored for gallbladder polyps measuring ≥ 6 mm.
Identifiants
pubmed: 39341964
doi: 10.1038/s41598-024-73429-1
pii: 10.1038/s41598-024-73429-1
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
22446Informations de copyright
© 2024. The Author(s).
Références
Wiles, R. et al. Management and follow-up of gallbladder polyps: joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other interventional techniques (EAES), International Society of Digestive Surgery - European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE). Eur. Radiol.27, 3856–3866 (2017).
doi: 10.1007/s00330-017-4742-y
pubmed: 28185005
pmcid: 5544788
Yamin, Z., Xuesong, B., Guibin, Y., Liwei, L. & Fei, L. Risk factors of gallbladder polyps formation in east Asian population: a meta-analysis and systematic review. Asian J. Surg.43, 52–59 (2020).
doi: 10.1016/j.hpb.2018.10.008
pubmed: 30416065
Patel, K., Dajani, K., Vickramarajah, S. & Huguet, E. Five year experience of gallbladder polyp surveillance and cost effective analysis against new European consensus guidelines. HPB (Oxford). 21, 636–642 (2019).
doi: 10.1007/s00330-021-08384-w
pubmed: 34918177
Foley, K. G. et al. Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE. Eur. Radiol.32, 3358–3368 (2022).
doi: 10.1016/j.asjsur.2019.03.015
pubmed: 31109764
Xu, Q. et al. Prevalences of and risk factors for biliary stones and gallbladder polyps in a large Chinese population. HPB (Oxford). 14, 373–381 (2012).
doi: 10.1111/j.1477-2574.2012.00457.x
pubmed: 22568413
Ahn, D. W. et al. Fatty liver is an independent risk factor for gallbladder polyps. World J. Gastroenterol.26(44), 6979–6992 (2020).
doi: 10.3748/wjg.v26.i44.6979
pubmed: 33311944
pmcid: 7701938
Lim, S. H. et al. Hepatic fat, not visceral fat, is associated with gallbladder polyps: a study of 2643 healthy subjects. J. Gastroenterol. Hepatol.30(4), 767–774 (2015).
doi: 10.1111/jgh.12841
pubmed: 25376159
Lee, J. K. et al. Visceral obesity is associated with gallbladder polyps. Gut Liver. 10(1), 133–139 (2016).
doi: 10.5009/gnl14506
pubmed: 26260756
pmcid: 4694745
Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol.73, 202–209 (2020).
doi: 10.1016/j.jhep.2020.03.039
pubmed: 32278004
Lazarus, J. V. et al. Reply: a multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 79(3), E93–E94 (2024).
pubmed: 37983810
Wong, V. W. S., Adams, L. A., de Lédinghen, V., Wong, G. L. & Sookoian, S. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat. Rev. Gastroenterol. Hepatol.15, 461–478 (2018).
doi: 10.1038/s41575-018-0014-9
pubmed: 29844588
Wai, J. W., Fu, C. & Wong, V. W. Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. J. Gastroenterol.55, 731–741 (2020).
doi: 10.1007/s00535-020-01686-8
pubmed: 32451628
pmcid: 7376510
Jeun, J. W. et al. Association of gallbladder polyp with the risk of colorectal adenoma. Intest Res.12, 48–52 (2014).
doi: 10.5217/ir.2014.12.1.48
pubmed: 25349563
pmcid: 4204683
Chartampilas, E. Imaging of nonalcoholic fatty liver disease and its clinical utility. Horm. (Athens). 17(1), 69–81 (2018).
doi: 10.1007/s42000-018-0012-x
Albert, P. S., Follmann, D. A. & Barnhart, H. X. A generalized estimating equation approach for modeling random length binary vector data. Biometrics. 53, 1116–1124 (1997).
doi: 10.2307/2533568
pubmed: 9290230
Yang, H. L. et al. Analysis of risk factors for polypoid lesions of gallbladder among health examinees. World J. Gastroenterol.18, 3015–3019 (2012).
doi: 10.3748/wjg.v18.i23.3015
pubmed: 22736927
pmcid: 3380331
Chen, C. H., Lin, C. L. & Kao, C. H. Association of gallbladder polyp and stroke: a nationwide, population-based study. Med. (Baltim).94, e2192 (2015).
doi: 10.1097/MD.0000000000002192
Kavanagh, K. et al. Estrogen decreases atherosclerosis in part by reducing hepatic acyl-CoA:cholesterol acyltransferase 2 (ACAT2) in monkeys. Arterioscler. Thromb. Vasc Biol.29, 1471–1477 (2009).
doi: 10.1161/ATVBAHA.109.191825
pubmed: 19759374
pmcid: 2763273
Kalbi, D. P., Bapatla, A., Chaudhary, A. J., Bashar, S. & Iqbal, S. Surveillance of gallbladder polyps: a literature review. Cureus. 13, e16113 (2021).
pubmed: 34350077
pmcid: 8325965
Park, E. J. et al. Association between metabolic syndrome and gallbladder polyps in healthy Korean adults. J. Korean Med. Sci.28, 876–880 (2013).
doi: 10.3346/jkms.2013.28.6.876
pubmed: 23772152
pmcid: 3678004
Lukanova, A. et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP – 1, -2 and – 3 and risk of endometrial cancer. Int. J. Cancer. 108, 262–268 (2004).
doi: 10.1002/ijc.11544
pubmed: 14639613
Mikolasevic, I. et al. Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipient and possible cause of an allograft dysfunction. Med. Hypotheses. 82, 36–39 (2014).
doi: 10.1016/j.mehy.2013.10.030
pubmed: 24280560
Mikolasevic, I. et al. Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients. Med. Hypotheses. 82, 205–208 (2014).
doi: 10.1016/j.mehy.2013.11.039
pubmed: 24365277
Li, Y., Yun, K. & Mu, R. A review on the biology and properties of adipose tissue macrophages involved in adipose tissue physiological and pathophysiological processes. Lipids Health Dis.19(1), 164 (2020).
doi: 10.1186/s12944-020-01342-3
pubmed: 32646451
pmcid: 7350193
John, B. J., Irukulla, S., Abulafi, A. M., Kumar, D. & Mendall, M. A. Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment. Pharmacol. Ther.23, 1511–1523 (2006).
doi: 10.1111/j.1365-2036.2006.02915.x
pubmed: 16696799
Kornprat, P., Rehak, P., Rüschoff, J. & Langner, C. Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours. J. Clin. Pathol.59, 202–206 (2006).
doi: 10.1136/jcp.2005.028480
pubmed: 16443739
pmcid: 1860307
Chapman, R. et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 51, 660–678 (2010).
doi: 10.1002/hep.23294
pubmed: 20101749
Buckles, D. C., Lindor, K. D., Larusso, N. F., Petrovic, L. M. & Gores, G. J. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am. J. Gastroenterol.97, 1138–1142 (2002).
doi: 10.1111/j.1572-0241.2002.05677.x
pubmed: 12014717
Chen, H. L. et al. Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. J. Biomed. Sci.25, 75 (2018).
doi: 10.1186/s12929-018-0475-8
pubmed: 30367658
pmcid: 6203212
Housset, C., Chrétien, Y., Debray, D. & Chignard, N. Functions of the gallbladder. Compr. Physiol.6, 1549–1577 (2016).
doi: 10.1002/cphy.c150050
pubmed: 27347902
Wu, L. et al. Changes in plasma bile acids are associated with gallbladder stones and polyps. BMC Gastroenterol.20, 363 (2020).
doi: 10.1186/s12876-020-01512-8
pubmed: 33129276
pmcid: 7603702
McCain, R. S., Diamond, A., Jones, C. & Coleman, H. G. Current practices and future prospects for the management of gallbladder polyps: a topical review. World J. Gastroenterol.24, 2844–2852 (2018).
doi: 10.3748/wjg.v24.i26.2844
pubmed: 30018479
pmcid: 6048427